Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials

Abstract EN

Aims.

To compare the efficacy and safety of vonoprazan-based versus proton pump inhibitor (PPI)-based triple therapy in the eradication of Helicobacter pylori.

Methods.

We performed a systematic search in PubMed, Embase, and the Cochrane Library databases for relevant randomized controlled trials up to March 2019.

Studies were included if they compared the efficacy and safety of H.

pylori eradication of vonoprazan-based and PPI-based triple therapy.

Results.

Three studies with 897 patients were evaluated in this meta-analysis.

The H.

pylori eradication rate of vonoprazan-based triple therapy was higher than that of PPI-based triple therapy as first-line regimens (intention-to-treat analysis: pooled eradication rates, 91.4% vs 74.8%; odds ratio [OR], 3.68; 95% confidence interval (CI): [1.87–7.26]; P<0.05).

The incidence of adverse events in vonoprazan-based triple therapy was lower than that in PPI-based triple therapy (pooled incidence, 32.7% vs 40.5%; OR, 0.71; 95%CI: [0.53–0.95]; P<0.05).

Conclusions.

Efficacy of vonoprazan-based triple therapy is superior to that of PPI-based triple therapy for first-line H.

pylori eradication.

Additionally, vonoprazan-based triple therapy is better tolerated than PPI-based triple therapy.